Raymond James Financial’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Raymond James Financial’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$905K	Sell	10,090 -476	-5%	-$39.2K	﹤0.01%	4071
2026 Q1	$837K	Buy	10,566 +651	+7%	+$52.6K	﹤0.01%	3982
2025 Q4	$815K	Buy	9,915 +1,837	+23%	+$142K	﹤0.01%	3918
2025 Q3	$564K	Buy	8,078 +141	+2%	+$9.53K	﹤0.01%	4039
2025 Q2	$509K	Sell	7,937 -1,159	-13%	-$71.8K	﹤0.01%	3999
2025 Q1	$577K	Sell	9,096 -9,782	-52%	-$658K	﹤0.01%	3848
2024 Q4	$1.26M	Buy	+18,878	New	+$1.3M	﹤0.01%	3293

Other funds holding PBE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Raymond James Financial's PBE Position: Q2 2026 in Review

Raymond James Financial reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 4.5% in Q2 2026, selling an estimated $39.2K and leaving 10,090 shares worth $905K. The position accounts for ﹤0.01% of the portfolio, ranked #4071.

Raymond James Financial first reported a position in PBE in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.26M in Q4 2024. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

Raymond James Financial held 10,090 shares of Invesco Biotechnology & Genome ETF worth $905K as of Q2 2026.
Raymond James Financial sold 476 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $39.2K.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4071 holding.
Raymond James Financial first reported a position in Invesco Biotechnology & Genome ETF in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Invesco Biotechnology & Genome ETF position peaked at $1.26M in Q4 2024.
105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.